Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Recursion Pharmaceuticals to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
This table compares Recursion Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Recursion Pharmaceuticals Competitors||-2,250.09%||-63.90%||-29.64%|
37.7% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for Recursion Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Recursion Pharmaceuticals Competitors||1575||5585||11279||206||2.54|
Recursion Pharmaceuticals currently has a consensus price target of $22.50, suggesting a potential upside of 275.00%. As a group, “Biological products, except diagnostic” companies have a potential upside of 108.36%. Given Recursion Pharmaceuticals’ higher probable upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than its rivals.
Earnings and Valuation
This table compares Recursion Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Recursion Pharmaceuticals||$10.18 million||-$186.48 million||-2.61|
|Recursion Pharmaceuticals Competitors||$776.76 million||$147.89 million||-1.02|
Recursion Pharmaceuticals’ rivals have higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Recursion Pharmaceuticals rivals beat Recursion Pharmaceuticals on 9 of the 12 factors compared.
About Recursion Pharmaceuticals (Get Rating)
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.